methylene blue
methylene blue: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.
methylene blue evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could methylene blue → NEXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| NEXUS BIOPHARMA INC (NEXS) Reported 2024-11-21 · Current development: unknownSource | Approved |
| NEXUS BIOPHARMA INC (NEXS) Reported 2024-11-21 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (1)
Adjunctive Methylene BLUe in Septic SHock: a Pilot Randomized Controlled Trial
Primary endpoint: Enrolment/Recruitment Rate
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with methylene blue?
methylene blue has dated SEC/FDA relationship records for NEXUS BIOPHARMA INC.
How many clinical trials involve methylene blue?
BioSniper tracks 1 clinical trial involving methylene blue.
What is methylene blue's latest FDA decision?
The most recent tracked FDA decision for methylene blue is Approval for 1 INDICATIONS AND USAGE Methylene blue injection is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. Methylene blue injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia., dated November 21, 2024.